Gender and age differences in the risk of allergic reactions following the Pfizer-BioNTech COVID-19 and AstraZeneca vaccine using skin prick test and intradermal test among patients with high risk for hypersensitivity
Main Article Content
Keywords
age, gender, COVID-19 vaccine, SPT, IDT
Abstract
Objective: The aim of this study was to assess the association between allergic reactions after COVID-19 vaccination and the history of high-risk allergy, individual predisposing factors such as age and gender, and COVID-19 vaccine type.
Materials and methods: This retrospective cohort study included 234 adult patients (18 years old and above) who underwent a COVID-19 vaccine allergy test up until February 2023 in a Clinic of Allergy and Clinical Immunology in the University Clinical Center of Kosovo. All patients suspected of allergy underwent skin testing: SPT (skin prick test) and IDT (intradermal test) using either an mRNA (ribonucleic messenger acid) vaccine (BNT162b2, Pfizer-BioNTech) and/or an adenoviral vector vaccine (AZD1222, AstraZeneca). Subsequent immunization was administered under careful medical observation.
Results: Among the 234 patients with a high-risk allergy profile, several potential risk factors were identified, including a history of multiple allergies, previous anaphylaxis, and/or drug allergies. In our cohort, food allergies were reported by 20 patients (8.5%) and multiple drug allergies were reported by 118 patients (50.4%). Due to the retrospective nature of the study, we cannot establish causality. Therefore, older age and receipt of the Pfizer-BioNTech vaccine were found to be associated with increased allergic reactions after COVID-19 vaccination, while male gender was associated with decreased risk. Although previous allergic manifestations were common among those with reactions, they were not significantly associated with increased risk after adjustment for confounders. The absence of a control group consisting of vaccinated individuals without a high-risk allergy history limits the generalizability of our findings.
Conclusions: Immediate allergic reactions to COVID-19 vaccines are rare but can be severe and reoccur. Findings suggest that gender and age-specific factors may influence the response to the vaccine. Nevertheless, COVID-19 vaccines remain a critical tool in preventing severe disease and controlling the ongoing pandemic.
References
2 WHO. COVID-19 vaccination, World data [Internet]. 2024. Available from: https://data.who.int/dashboards/covid19/vaccines?n=o
3 Deb B, Shah H, Goel S. Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials. J Biosci. 2020;45(1):82. 10.1007/s12038-020-00053-2
4 Shavit R, Maoz-Segal R, Iancovici-Kidon M, Offengenden I, Haj Yahia S, Machnes Maayan D, et al. Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk. JAMA Netw Open. 2021;4(8):e2122255. 10.1001/jamanetworkopen.2021.22255
5 McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–72. 10.1016/j.jaci.2017.12.971
6 Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–6. 10.1038/d41573-020-00073-5
7 Yaamika H, Muralidas D, Elumalai K. Review of adverse events associated with COVID-19 vaccines, highlighting their frequencies and reported cases. J Taibah Univ Med Sci. 2023;18(6):1646–61. 10.1016/j.jtumed.2023.08.004
8 Li YE, Wang S, Reiter RJ, Ren J. Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: From dream to reality? Int J Infect Dis. 2022;124:1–10. 10.1016/j.ijid.2022.08.026
9 Rosenblatt AE, Stein SL. Cutaneous reactions to vaccinations. Clin Dermatol. 2015;33(3):327–32. 10.1016/j.clindermatol.2014.12.009
10 Fiorillo G, Pancetti S, Cortese A, Toso F, Manara S, Costanzo A, et al. Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination. J Autoimmun. 2022;127:102783. 10.1016/j.jaut.2021.102783
11 Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293–302. 10.1016/S1473-3099(22)00320-6
12 Rashiti-Bytyçi A, White Johansson E, Kaçaniku-Gunga P, Danis K, Schoeps A, Dörre A, et al. Estimation of COVID-19 vaccine effectiveness against infections and severe outcomes using routine surveillance data in Kosovo, July–September 2021. Jakupi A, editor. PLoS One. 2024;19(7):e0305629. 10.1371/journal.pone.0305629
13 Chen W, Mempel M, Schober W, Behrendt H, Ring J. Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy. 2008;63(11):1418–27. 10.1111/j.1398-9995.2008.01880.x
14 Leynaert B, Sunyer J, Garcia-Esteban R, Svanes C, Jarvis D, Cerveri I, et al. Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: A population-based cohort. Thorax. 2012;67(7):625–31. 10.1136/thoraxjnl-2011-201249
15 Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA, Davis MM, et al. Prevalence and severity of food allergies among US adults. JAMA Netw Open. 20194;2(1):e185630. 10.1001/jamanetworkopen.2018.5630
16 Dhopeshwarkar N, Sheikh A, Doan R, Topaz M, Bates DW, Blumenthal KG, et al. Drug-induced anaphylaxis documented in electronic health records. J Allergy Clin Immunol Pract. 2019;7(1):103–11. 10.1016/j.jaip.2018.06.010
17 Blumenthal KG, Robinson LB, Camargo CA, Shenoy ES, Banerji A, Landman AB, et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562–5. 10.1001/jama.2021.3976
18 Esposito D, Titievsky L, Beachler DC, Hawes JCL, Isturiz R, Scott DA, et al. Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population. Vaccine. 201818;36(52):8084–93. 10.1016/j.vaccine.2018.10.052
19 Green MS, Peer V, Magid A, Hagani N, Anis E, Nitzan D. Gender differences in adverse events following the Pfizer-BioNTech COVID-19 vaccine. Vaccines. 2022;10(2):233. 10.3390/vaccines10020233
20 Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471–84. 10.1161/CIRCULATIONAHA.121.056135
21 Clothier HJ, Lawrie J, Lewis G, Russell M, Crawford NW, Buttery JP. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, Australia, 2018. Commun Dis Intell. 2020;15:44. 10.33321/cdi.2020.44.46
22 Harris T, Nair J, Fediurek J, Deeks SL. Assessment of sex-specific differences in adverse events following immunization reporting in Ontario, 2012–15. Vaccine. 2017;35(19):2600–4. 10.1016/j.vaccine.2017.03.035
23 Alguacil-Ramos AM, Muelas-Tirado J, Garrigues-Pelufo TM, Portero-Alonso A, Diez-Domingo J, Pastor-Villalba E, et al. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system. Public Health. 2016;135:66–74. 10.1016/j.puhe.2015.11.010
24 Tadount F, Doyon-Plourde P, Rafferty E, MacDonald S, Sadarangani M, Quach C. Is there a difference in the immune response, efficacy, effectiveness and safety of seasonal influenza vaccine in males and females?–A systematic review. Vaccine. 2020;38(3):444–59. 10.1016/j.vaccine.2019.10.091
25 Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine—United States, December 14–23, 2020. MMWR Morb Mortal Wkly Rep. 2021;70(2):46–51. 10.15585/mmwr.mm7002e1
26 Bunyavanich S, Rifas-Shiman SL, Platts-Mills TAE, Workman L, Sordillo JE, Gillman MW, et al. Peanut allergy prevalence among school-age children in a US cohort not selected for any disease. J Allergy Clin Immunol 2014 Sep;134(3):753–5. 10.1016/j.jaci.2014.05.050
27 Li L, Robinson LB, Patel R, Landman AB, Fu X, Shenoy ES, et al. Association of self-reported high-risk allergy history with allergy symptoms after COVID-19 vaccination. JAMA Netw Open. 2021;4(10):e2131034. 10.1001/jamanetworkopen.2021.31034